COVID-19, Lymphocytopenia
Conditions
Brief summary
Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients
Detailed description
Approximately forty-eight (48) participants will be randomized 1:1 to receive (a) Intramuscular (IM) administration of CYT107 at 10 μg/kg followed, after 72hrs of observation, by 10 μg/kg twice a week for 3 weeks (maximum 7 administrations adjusted to patient's length of stay in the hospital) or (b) Intramuscular (IM) placebo (normal saline) at the same frequency. The aim of the study is to test the ability of CYT107 to produce an immune reconstitution of these patients and observe possible association with a clinical improvement. This cohort is dedicated to oncology patients
Interventions
DRUGCYT107
IM administration at 10µg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
DRUGPlacebo
Same number, volume and frequency of IM administration of saline
Sponsors
Memorial Sloan Kettering Cancer Center
Amarex Clinical Research
M.D. Anderson Cancer Center
Cancer Research Institute, New York City
Revimmune
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Unblinded Pharmacist will prepare blinded syringes of colorless drug or placebo
Intervention model description
randomized controlled of treatment vs placebo
Eligibility
Sex/Gender
ALL
Age
25 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. A written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing Study participation 2. Patient receiving active or recent chemotherapy or immunotherapy (within 6 months) for cancer (and/or) 3. Patients who have received hematopoietic stem cell transplantation (for a diagnosis other than lymphoma) within the past 1 year (and/or) 4. Patients who received CAR-T cell therapy within the past 1 year (but not within last 30 days- see also
Exclusion criteria
number 6 & 7) (and/or) 5. Patients receiving hormonal therapy for cancer (and/or) 6. Patients who have undergone surgery or radiotherapy for cancer within the past 6 months 7. Patients with newly diagnosed (biopsy proven) malignancy who have not yet received cancer treatment but get COVID pneumonia in the interim (Incl. Criteria 11) 8. Men and women aged ≥ 25 - 80 (included) years of age 9. Hospitalized patients with one absolute lymphocyte count (ALC) ≤ 1000 cells/mm3, collected at baseline or no more than 72h before baseline . From this time point the investigator may choose to further postpone the commencement of IL-7 (CYT107) treatment according to patient's clinical status. 10. Hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at \>4L per minute nasal cannula or greater to keep saturations \>90%, non-invasive positive pressure ventilation (e.g., BIPAP), or patients intubated/ventilated for respiratory failure 11. Confirmed infection with COVID-19 by any acceptable test available/utilized at each site 12. Willingness and ability to practice contraception regardless of the gender of the patient during 5 months after last drug exposure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC≤1000/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whichever occurs first | one month | A statistically significant increase of the absolute lymphocyte count (ALC) from randomization to day 30 or HospitalDischarge |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To obtain clinical improvement as defined by an improvement in a 11-points WHO score for Clinical Assessment, through day 30 or HD. | one month | to determine if CYT107 will improve the clinical status of hospitalized COVID-19 patients as measured by 11 steps WHO clinical improvement score |
| a significant decline of SARS-CoV-2 viral load through day 30 or HD | 1 month or HD (whichever occurs first) | The decrease of SARS-CoV-2 viral load from measurements at baseline and days of treatment dose 4 and dose 5, Day 21 and Day 30 or HD (whichever occurs first) |
| frequency of secondary infections through day 45 compared to placebo arm | 45 days | Incidence of secondary infections based on pre-specified criteria as adjudicated by the Secondary Infections Committee (SIC) through Day 45 |
| length of hospitalization compared to placebo arm | 45 days | Number of days of hospitalization during index hospitalization (defined as time from initial Study drug treatment through HD) |
| length of stay in ICU compared to placebo arm | 45 days | Number of days in ICU during index hospitalization |
| number of readmissions to ICU compared to placebo arm | 45 days | Readmissions to ICU through Day 45 |
| organ support free days compared to placebo arm | 45 days | Organ support free days (OSFDs) during index hospitalization (This includes ventilator assistance free days) |
| All-cause mortality through day 45 compared to placebo arm | 45 days | All-cause mortality through Day 45 |
| CD4+ and CD8+ T cell counts compared to placebo arm | 30 days | Absolute numbers of CD4+ and CD8+ T-cell counts at time points indicated on the Schedule of Activities (SoA) through Day 30 or HD |
| level of other known biomarkers of inflammation: Ferritin compared to placebo arm | 30 days | Track and evaluate other known biomarkers of inflammation, Ferritin, from baseline to day 30 |
| Level of other known biomarkers of inflammation: CRP compared to placebo arm | 30 days | Track and evaluate other known biomarkers of inflammation, CRP from baseline to day 30 |
| Level of other known biomarkers of inflammation: D-dimer compared to placebo arm | 30 days | Track and evaluate other known biomarkers of inflammation, D-dimer from baseline to day 30 |
| Physiological status through NEWS2 evaluation compared to Placebo arm | 30 days | Evaluate improvement of the NEWS2 score value. Score form 0 to 4: NO Risk Score of 7 or more: High risk |
| Frequency of re-hospitalization through day 45 compared to placebo arm | 45 days | Number of readmissions to the hospital through Day 45 |
Other
| Measure | Time frame | Description |
|---|---|---|
| Safety assessment through incidence and scoring of grade 3-4 adverse events | 45 days | Incidence and scoring of all grade 3-4 adverse events through Day 45 (using CTCAE Version 5.0) to assess safety |
Countries
United States
Outcome results
None listed